Allopurinol Add‐on 6‐Mercaptopurine Strategy Improves Efficacy and Reduces Toxicity in Pediatric Patients With Acute Lymphoblastic Leukemia
Clinical Pharmacology & Therapeutics · 2026
DOI: 10.1002/cpt.70123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2026. Verfasst von Yanping Guan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Pharmacology, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, GD, China. Hauptthemen laut MEDLINE: Allopurinol, Mercaptopurine, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province, National Key Research and Development Program.
Abstract (Originalsprache)
The short‐term efficacy of allopurinol add‐on thiopurine therapy has been well documented; however, the long‐term effects and dose recommendations are poorly detailed. This study aimed to elucidate the long‐term implications of this combination therapy and to develop initial dose applying pharmacokinetic modeling. Forty‐two pediatric patients with acute lymphoblastic leukemia, treated with 6‐mercaptopurine (6‐MP) and allopurinol, were enrolled in this prospective before‐after pharmacokinetic study. Metabolite levels (6‐thioguanine nucleotides (6‐TGNs), methyl mercaptopurine nucleotides (6‐MMPN), DNA‐thioguanine (DNA‐TG)), thiopurine methyltransferase (TPMT) activity were measured pre‐ and post‐combination. Another retrospective cohort of 40 patients receiving 6‐MP monotherapy was taken as controls. Compared with the control group, the combination therapy showed a similar myelosuppression effect (( P = 0.060, adjusted Hazard Rates, aHR = 0.94 (0.89–1.00)), while markedly reducing the cumulative hazard of severe neutropenia ( P = 0.009, aHR = 0.49 (0.28–0.83)) and hepatotoxicity ( P < 0.001, aHR = 0.54 (0.40–0.73)). Allopurinol combination led to a fourfold reduction in TPMT activity, the 6‐MMPN:6‐TGNs ratios, and 6‐MMPN: DNA‐TG ratios. This metabolic adjustment improved control of white blood cell (WBC) counts, neutrophil counts (ANC), and aminotransferase levels. LOESS regression estimates indicated significant fluctuations in WBC, ANC, and 6‐MP/allopurinol dosage ratios following 3 months of combination therapy ( P < 0.001), reflecting the need for close monitoring and frequent dose adjustments. Pharmacokinetic analysis further reinforces the benefits of allopurinol add‐on 6‐MP strategy, and suggested that, for patients with normal or high TPMT activity, an initial 6‐MP dose of 20–30 mg/m 2 /day is recommended for those with BSA ≤ 1 m 2 , and 15–20 mg/m 2 /day for those with BSA > 1 m 2 , when co‐administered with allopurinol (50 mg/m 2 /day).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Clinical Pharmacology, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, GD, China.
- Department of Pediatrics, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, GD, China.
- Department of Pharmacy, Shenzhen People's Hospital, Shenzhen, GD, China.
- School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China.
- State Key Laboratory of Research on Bioactivities and Clinical Applications of Medicinal Plants, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China.
- Children's Medical Center and Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
ORCID-Profile: Yanping Guan, Xiaoli Zhang, Sumyuet Chan, Shan Su, Qiaolan Xuan, Ting Yang, Xuequn Luo, Zhong Zuo, Dunhua Zhou, Min Huang, Xueding Wang, Libin Huang
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province
- National Key Research and Development Program
- Guangdong Provincial Key Laboratory of Construction Foundation
- National Key Research and Development Program of China
Zitieren
APA
Guan, Y., Zhang, X., Chan, S., Su, S., Xuan, Q., Yang, T., Luo, X., Zuo, Z., Zhou, D., Huang, M., Wang, X., & Huang, L. (2026). Allopurinol Add‐on 6‐Mercaptopurine Strategy Improves Efficacy and Reduces Toxicity in Pediatric Patients With Acute Lymphoblastic Leukemia. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70123
Vancouver
Guan Y, Zhang X, Chan S, Su S, Xuan Q, Yang T, et al. Allopurinol Add‐on 6‐Mercaptopurine Strategy Improves Efficacy and Reduces Toxicity in Pediatric Patients With Acute Lymphoblastic Leukemia. Clinical Pharmacology & Therapeutics. 2026. doi:10.1002/cpt.70123
BibTeX
@article{Guan2026,
author = {Guan, Yanping and Zhang, Xiaoli and Chan, Sumyuet and Su, Shan and Xuan, Qiaolan and Yang, Ting and Luo, Xuequn and Zuo, Zhong and Zhou, Dunhua and Huang, Min and Wang, Xueding and Huang, Libin},
title = {Allopurinol Add‐on 6‐Mercaptopurine Strategy Improves Efficacy and Reduces Toxicity in Pediatric Patients With Acute Lymphoblastic Leukemia},
journal = {Clinical Pharmacology & Therapeutics},
year = {2026},
doi = {10.1002/cpt.70123}
}
EUVIMED